Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development
Innovative therapies to complement current treatments are needed to curb the growing incidence of fatal overdoses related to synthetic opioids. Murine and chimeric monoclonal antibodies (mAb) specific for fentanyl and its analogs have demonstrated pre-clinical efficacy in preventing and reversing dr...
Saved in:
Main Authors: | Dustin Hicks (Author), Carly Baehr (Author), Pedro Silva-Ortiz (Author), Aaron Khaimraj (Author), Diego Luengas (Author), Fatima A. Hamid (Author), Marco Pravetoni (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel chimeric monoclonal antibodies that block fentanyl effects and alter fentanyl biodistribution in mice
by: Bhupal Ban, et al.
Published: (2021) -
Advances in the progress of monoclonal antibodies for rabies
by: Linlin Fan, et al.
Published: (2022) -
Advances and challenges in therapeutic monoclonal antibodies drug development
by: Mariana Lopes dos Santos, et al.
Published: (2018) -
Monoclonal Antibodies
Published: (2021) -
Monoclonal Antibodies
by: Christian Klein (Ed.)
Published: (2018)